Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iris K Minichmayr

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Clinical Pharmacokinetics|May 3, 2019
Comment on "Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients"Iris K Minichmayr, Markus Zeitlinger
The New England Journal of Medicine|September 3, 2025
Malnutrition in Older AdultsIris K Minichmayr, Markus Zeitlinger
Clinical Pharmacology and Therapeutics|March 18, 2026
Pharmacogenetics-Not Just Low-Hanging FruitIngolf Cascorbi, Iris K Minichmayr
International Journal of Antimicrobial Agents|June 8, 2024
Impact of continuous-infusion meropenem degradation and infusion bag changes on bacterial killing of Pseudomonas aeruginosa based on model-informed translationIris K Minichmayr, Lena E Friberg
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 20, 2013
Population pharmacokinetics meets microdialysis: benefits, pitfalls and necessities of new analysis approaches for human microdialysis dataAndré Schaeftlein, Iris K Minichmayr, Charlotte Kloft
Pharmaceutical Research|March 18, 2021
Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan SafetyIris K Minichmayr, Mats O Karlsson, Siv Jönsson
International Journal of Antimicrobial Agents|June 12, 2022
Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effectsIris K Minichmayr, Vincent Aranzana-Climent, Lena E Friberg
Pharmaceutical Research|December 20, 2024
A Model-Based Evaluation of Noninvasive Biomarkers to Reflect Histological Nonalcoholic Fatty Liver Disease ScoresIris K Minichmayr, Elodie L Plan, Benjamin Weber, et al.
Clinical Pharmacokinetics|October 19, 2016
Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill PatientsIris K Minichmayr, André Schaeftlein, Joseph L Kuti, et al.
Antibiotics (Basel, Switzerland)|August 26, 2022
Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against <i>Pseudomonas aeruginosa</i> to Clinical SettingsIris K Minichmayr, Suzanne Kappetein, Margreke J E Brill, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Clinical Pharmacokinetics|May 3, 2019
Comment on "Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients"Iris K Minichmayr, Markus Zeitlinger
The New England Journal of Medicine|September 3, 2025
Malnutrition in Older AdultsIris K Minichmayr, Markus Zeitlinger
Clinical Pharmacology and Therapeutics|March 18, 2026
Pharmacogenetics-Not Just Low-Hanging FruitIngolf Cascorbi, Iris K Minichmayr
International Journal of Antimicrobial Agents|June 8, 2024
Impact of continuous-infusion meropenem degradation and infusion bag changes on bacterial killing of Pseudomonas aeruginosa based on model-informed translationIris K Minichmayr, Lena E Friberg
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 20, 2013
Population pharmacokinetics meets microdialysis: benefits, pitfalls and necessities of new analysis approaches for human microdialysis dataAndré Schaeftlein, Iris K Minichmayr, Charlotte Kloft
Pharmaceutical Research|March 18, 2021
Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan SafetyIris K Minichmayr, Mats O Karlsson, Siv Jönsson
International Journal of Antimicrobial Agents|June 12, 2022
Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effectsIris K Minichmayr, Vincent Aranzana-Climent, Lena E Friberg
Pharmaceutical Research|December 20, 2024
A Model-Based Evaluation of Noninvasive Biomarkers to Reflect Histological Nonalcoholic Fatty Liver Disease ScoresIris K Minichmayr, Elodie L Plan, Benjamin Weber, et al.
Clinical Pharmacokinetics|October 19, 2016
Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill PatientsIris K Minichmayr, André Schaeftlein, Joseph L Kuti, et al.
Antibiotics (Basel, Switzerland)|August 26, 2022
Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against <i>Pseudomonas aeruginosa</i> to Clinical SettingsIris K Minichmayr, Suzanne Kappetein, Margreke J E Brill, et al.
Pageof 4